#407 ‒ Preventing cardiovascular and Alzheimer's disease: lowering LDL early, APOE4, and promising new therapies | Michael Davidson, M.D.

In this episode of The Drive, Dr. Peter Attia sits down with Dr. Michael Davidson, a distinguished cardiologist and lipidologist, to delve into the intricate world of lipid management, cardiovascular disease prevention, and the burgeoning field of Alzheimer's research. Their conversation spans the importance of early intervention in lowering LDL, the complex interplay of genetics and lifestyle, and the exciting prospects of novel therapeutic agents.

The Path to Lipidology and Early Prevention

Dr. Davidson's journey into lipidology was deeply personal, spurred by the tragic loss of his father to a heart attack at age 47 when Davidson was just 16. This early exposure to the devastating impact of cardiovascular disease, coupled with his own abnormal lipid profile and a strong family history, ignited a lifelong passion for prevention. He recounts his early involvement in niacin trials in the 1980s and his pioneering work with fish oil capsules for lipid disorders, eventually leading him to participate in numerous statin trials. Davidson emphasizes that while he still practices cardiology, his primary focus has always been on prevention, establishing a prevention center and research organization early in his career.

Attia and Davidson discuss the prevailing medical approach, which often waits for significant plaque buildup or a cardiovascular event before aggressive treatment. Davidson challenges this, advocating for a "primal prevention" concept: stopping plaque formation before it even begins. He introduces the "8-gram rule," a powerful heuristic suggesting that accumulating 8 grams of cholesterol in one's lifetime leads to heart disease. This translates to maintaining an LDL-C below 80 mg/dL throughout life to prevent heart disease entirely. Davidson argues that the knowledge and tools to prevent heart disease are already available; the challenge lies in applying them earlier in life, particularly for individuals in their 20s and 30s. He notes that while family history is a strong motivator, it's not always sufficient to convince younger patients to adopt aggressive preventive measures, necessitating additional tools like genetic testing, polygenic risk scores, and coronary calcium scanning.